Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant Recipients

Exclusion Criteria

• •1. Patients who had received non-liver organs before liver transplantation or had received other organs while receiving liver.
• •2. Patients who had auxiliary partial orthotopic liver transplantation or had bioartifical liver
• •3. Patients who have been diagnosed with acute rejection within 6 months and have been treated
• •4. Patients who had hepatic artery complication such as hepatic artery thrombosis within recent 6 months
• •5. Patients who have been diagnosed with malignant tumor within 5 years(however, the following will be excepted)
• •* fully recovered from skin cancer(squamous cell/basal cell carcinoma or thyroid cancer)
• •* haptocellular carcinoma without main vessel invasion
• •6. Patients with severe systemic infection
• •7. Patients who are difficult to communicate due to mental disorder
• •8. Patients who are in treatment for hapatitis, or are over 3 times higher than upper normal limit in liver function test(T-bilirubin, AST, ALT) or over 5 times higher than normal limit of ALP
• •9. Patients who are(at screening visit)
• •* WBC\<1,500/mm\^3
• •* PLT\<30,000/mm\^3
• •* over 1.0 in Protein/creatinine ratio(UA test)
• •* eGFR\<30mL/min/1.73m\^2(MDRD)
• •* Total Cholesterol\>350mg/dL or Triglycerides\>500mg/dL
• •10. Patients taking HCV(hapatitis C virus) therapeutic drug or anti-HCV positive patients who have positive result in HCV RNA test at screening visit
• •11. Patients who had plasmapheresis within 1 week
• •12. Those who are pregnant, nursing, or are not practicing contraception with appropriate method
• •13. Patients who had plasmapheresis within 3 months
• •14. if participated in other trail within 4 weeks(28 days)
• •15. In investigator's judgement